HK1062198A1 - Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xi and bcl-w proteins - Google Patents

Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xi and bcl-w proteins

Info

Publication number
HK1062198A1
HK1062198A1 HK04103329A HK04103329A HK1062198A1 HK 1062198 A1 HK1062198 A1 HK 1062198A1 HK 04103329 A HK04103329 A HK 04103329A HK 04103329 A HK04103329 A HK 04103329A HK 1062198 A1 HK1062198 A1 HK 1062198A1
Authority
HK
Hong Kong
Prior art keywords
bcl
proteins
screening
binding
pp1c
Prior art date
Application number
HK04103329A
Other languages
English (en)
Inventor
Alphonse Garcia
Xavier Cayla
Angelita Rebollo
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of HK1062198A1 publication Critical patent/HK1062198A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
HK04103329A 2002-05-07 2004-05-12 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xi and bcl-w proteins HK1062198A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291170A EP1361439B1 (de) 2002-05-07 2002-05-07 Screeningverfahren für Peptide, die die Bindung von PP1c an Bcl-2, BCL-Xl und BCL-W Proteine inhibieren

Publications (1)

Publication Number Publication Date
HK1062198A1 true HK1062198A1 (en) 2004-10-21

Family

ID=29225746

Family Applications (3)

Application Number Title Priority Date Filing Date
HK04103329A HK1062198A1 (en) 2002-05-07 2004-05-12 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xi and bcl-w proteins
HK05106078A HK1078337A1 (en) 2002-05-07 2005-07-18 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins
HK08113241.2A HK1119249A1 (en) 2002-05-07 2008-12-04 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK05106078A HK1078337A1 (en) 2002-05-07 2005-07-18 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins
HK08113241.2A HK1119249A1 (en) 2002-05-07 2008-12-04 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins

Country Status (13)

Country Link
US (2) US7741288B2 (de)
EP (4) EP1361439B1 (de)
AT (4) ATE434186T1 (de)
AU (1) AU2003242569A1 (de)
CA (1) CA2484211A1 (de)
CY (2) CY1107367T1 (de)
DE (4) DE60216048T2 (de)
DK (3) DK1788394T3 (de)
ES (3) ES2327773T3 (de)
HK (3) HK1062198A1 (de)
PT (3) PT1361439E (de)
SI (1) SI1502116T1 (de)
WO (1) WO2003096022A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP2142571A4 (de) * 2007-05-02 2010-05-05 Intrexon Corp Pp1-liganden
EP2348038A1 (de) * 2010-01-22 2011-07-27 Philipps-Universität Marburg Verfahren zur Bestimmung der Aktivität der Transglutaminase Faktor XIIIa
EP3708170A1 (de) * 2014-05-05 2020-09-16 BioVentures, LLC Zusammensetzungen und verfahren zur hemmung von antiapoptotischen bcl-2-proteinen als anti-aging mittel
US20170056422A1 (en) * 2014-05-07 2017-03-02 Seattle Biomedical Research Institute Plasmodium liver-stage inhibitors and related methods
JP2017522388A (ja) 2014-07-22 2017-08-10 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 老化細胞を選択的に枯渇させるための組成物及び方法
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN108218962B (zh) * 2017-12-29 2021-06-08 广西中医药大学 小分子多肽及其用途
CA3088253A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (de) 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
ATE398287T1 (de) * 1996-03-30 2008-07-15 Medical Res Council Wechselwirkungen der katalytischen untereinheit der proteinphosphatase 1
JP4544715B2 (ja) * 1999-08-17 2010-09-15 成男 太田 ラットｂｃｌ−ｘ遺伝子の改変型ｃＤＮＡと改変型タンパク質
WO2002072601A2 (en) * 2001-02-07 2002-09-19 The Burnham Institute Apoptosis modulator bcl-b and methods for making and using same
WO2002074931A2 (en) * 2001-03-20 2002-09-26 University Of Chicago Inhibitors and disassemblers of fibrillogenesis
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
SI1502116T1 (sl) 2008-06-30
CA2484211A1 (en) 2003-11-20
EP1502116A2 (de) 2005-02-02
DE60318427T2 (de) 2008-12-18
ATE345504T1 (de) 2006-12-15
ATE382864T1 (de) 2008-01-15
CY1107367T1 (el) 2012-12-19
CY1109383T1 (el) 2014-07-02
ES2327773T3 (es) 2009-11-03
DE60232691D1 (de) 2009-07-30
WO2003096022A8 (en) 2004-06-03
EP1788394A1 (de) 2007-05-23
ES2276895T3 (es) 2007-07-01
DE60318427D1 (de) 2008-02-14
EP1361439B1 (de) 2006-11-15
HK1119249A1 (en) 2009-02-27
US20110028387A1 (en) 2011-02-03
ATE472104T1 (de) 2010-07-15
AU2003242569A1 (en) 2003-11-11
US7741288B2 (en) 2010-06-22
EP1788394B1 (de) 2009-06-17
DE60216048D1 (de) 2006-12-28
DK1502116T3 (da) 2008-05-13
HK1078337A1 (en) 2006-03-10
EP1361439A1 (de) 2003-11-12
DK1788394T3 (da) 2009-10-19
PT1788394E (pt) 2009-08-13
PT1502116E (pt) 2008-04-15
DE60333138D1 (de) 2010-08-05
ATE434186T1 (de) 2009-07-15
EP1502116B1 (de) 2008-01-02
WO2003096022A2 (en) 2003-11-20
DK1361439T3 (da) 2007-03-26
EP1933150B1 (de) 2010-06-23
ES2300603T3 (es) 2008-06-16
AU2003242569A8 (en) 2003-11-11
PT1361439E (pt) 2007-02-28
US20050244844A1 (en) 2005-11-03
WO2003096022A3 (en) 2004-04-01
DE60216048T2 (de) 2007-05-31
EP1933150A1 (de) 2008-06-18

Similar Documents

Publication Publication Date Title
HK1119249A1 (en) Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
EP2204189A3 (de) Peptidfragemente von Allergenen und deren Verwendung
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2009004315A8 (en) Isolated peptides and uses thereof
Schneider et al. Posttranslational modifications of trichomonad tubulins; identification of multiple glutamylation sites
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
SE9503679D0 (sv) Antioxidants
ATE362487T1 (de) N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
WO2003010184A3 (en) A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
WO2004072223A3 (en) Identification and characterization of racemases, definition of protein signatures, and a test for detecting d-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase
WO2006097336A3 (en) A novel component of the wg/wnt signaling pathway
ATE405827T1 (de) Screening-verfahren
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods
AU2003902414A0 (en) Flowering induction
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
EP1455186A4 (de) Screening-verfahren
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2003102209A3 (en) Alternatively spliced isoforms of human hmg co-a reductase
WO2004076473A3 (en) Androgen receptor interacting peptides
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
WO2002074804A3 (en) Use of binding domains of presenilins and transmembrane proteins for drug screening
WO2002061074A1 (fr) Nouvelle proteine et adn la comprenant
WO2004011491A3 (en) Peptidyl-trna hydrolase of enterococcus faecalis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110507